We are live on ! Find out more

476 hedge funds and large institutions have $10.1B invested in Sanofi in 2016 Q4 according to their latest regulatory filings, with 81 funds opening new positions, 124 increasing their positions, 187 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 81 | Existing positions closed: 45

6% more funds holding

Funds holding: 450476 (+26)

5% more capital invested

Capital invested by funds: $9.66B → $10.1B (+$471M)

0.18% less ownership

Funds ownership: 19.62%19.43% (-0.18%)

15% less call options, than puts

Call options by funds: $46.5M | Put options by funds: $54.8M

22% less funds holding in top 10

Funds holding in top 10: 97 (-2)

34% less repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 187

Holders
476
Holders Change
+26
Holders Change %
+5.78%
% of All Funds
11.88%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.17%
New
81
Increased
124
Reduced
187
Closed
45
Calls
$46.5M
Puts
$54.8M
Net Calls
-$8.31M
Net Calls Change
-$31.9M

SNY Hedge Fund Activity: Q4 2016 in Review

476 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q4 2016, worth a combined $10.1B — up 4.9% from $9.66B a quarter earlier.

Buyers outnumbered sellers: 81 funds opened new SNY positions and 45 closed out — a net gain of 36 holders — while 124 added to existing stakes and 187 trimmed.

The largest buyer was Dodge & Cox, adding an estimated $364M. The largest seller was Barrow, Hanley, Mewhinney & Strauss, cutting an estimated $76.6M.

  • 476 institutional investors held Sanofi (SNY) as of Q4 2016, up from 450 in Q3 2016.
  • Funds reported $10.1B of Sanofi stock for Q4 2016, up 4.9% quarter-over-quarter.
  • 81 funds opened new Sanofi positions in Q4 2016 and 45 closed out, a net change of +36 holders.
  • The largest Sanofi buyer in Q4 2016 was Dodge & Cox, an estimated $364M added.
  • The largest Sanofi seller in Q4 2016 was Barrow, Hanley, Mewhinney & Strauss, an estimated $76.6M sold.

Based on aggregated 13F filings for Q4 2016.